Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 6/20 | 0.37 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6676290 | 0.94 | SLC6A2 (0.41) | SLC6A2SLC6A4OPRM1OPRL1TMEM97 | |
| SCHEMBL6677450 | 0.92 | TMEM97 (0.40) | SLC6A2SLC6A4OPRM1OPRL1TMEM97 | |
| SCHEMBL6676712 | 0.90 | SLC6A4 (0.38) | SLC6A2SLC6A4OPRM1OPRL1SIGMAR1 | |
| SCHEMBL6679404 | 0.89 | SLC6A2 (0.42) | SLC6A2SLC6A4OPRM1OPRL1SIGMAR1 | |
| SCHEMBL6940299 | 0.89 | SLC6A2 (0.44) | SLC6A2SLC6A4OPRM1OPRL1TMEM97 | |
| SCHEMBL6675795 | 0.88 | OPRM1 (0.38) | OPRM1OPRL1SLC18A3OPRD1OPRK1 | |
| SCHEMBL6676948 | 0.87 | OPRM1 (0.38) | OPRM1OPRL1SLC18A3OPRD1OPRK1 | |
| SCHEMBL6677715 | 0.87 | OPRM1 (0.37) | OPRM1OPRL1SLC18A3OPRD1OPRK1 | |
| SCHEMBL6676667 | 0.86 | SLC6A2 (0.40) | SLC6A2SLC6A4OPRM1OPRL1SIGMAR1 | |
| SCHEMBL6681024 | 0.85 | SLC6A4 (0.39) | SLC6A2SLC6A4OPRM1OPRL1SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1289514-B1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-11-03 | — | — | EP | claimed |
| US-6784175-B2 | WITH AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTIC EFFECT | GRUENENTHAL GMBH (DE) | 2004-08-31 | — | — | US | claimed |
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-09-25 | — | — | US | claimed |
| EP-1289514-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-03-12 | — | — | EP | claimed |
| WO-2001089505-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2001-11-29 | — | — | WO | claimed |
| EP-1289514-B1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | GRUENENTHAL GMBH (DE) | 2004-11-03 | — | — | EP | disclosed |
| US-6784175-B2 | WITH AN N-METHYL-D-ASPARTATE (NMDA) ANTAGONISTIC EFFECT | GRUENENTHAL GMBH (DE) | 2004-08-31 | — | — | US | disclosed |
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRUENENTHAL GMBH (DE) | 2003-09-25 | — | — | US | disclosed |
| EP-1289514-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2003-03-12 | — | — | EP | disclosed |
| WO-2001089505-A1 | USE OF SUBSTITUTED 1-AMINO-5-PHENYLPENTANE-3-OL AND/OR 1-AMINO-6-PHENYLHEXANE-3-OL COMPOUNDS AS MEDICAMENTS | Grünenthal GmbH (DE) | 2001-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030181450-A1 | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | GRIN3A, GRIN1, GRIN3B | SLC6A2 199/4885SLC6A4 108/4885OPRM1 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.